Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | 60 Months Ended | |||
|---|---|---|---|---|---|---|---|
Dec. 22, 2017 |
Jun. 30, 2018 |
Jun. 30, 2017 |
Jun. 30, 2018 |
Jun. 30, 2017 |
Dec. 31, 2017 |
Dec. 31, 2017 |
|
| Patent and licensing costs | $ 243,153 | $ 172,394 | $ 460,813 | $ 487,748 | |||
| Minimum concentration of risk percent | 10.00% | ||||||
| Deferred setup and organization costs, amortization period | 180 months | ||||||
| Unrecognized tax benefits | |||||||
| Tax Reform Law [Member] | |||||||
| Federal corporate tax rate | 21.00% | ||||||
| Income tax reconciliation description | The Tax Reform Act reduces the federal corporate tax rate from 35% to 21% effective January 1, 2018 | ||||||
| Theradex Systems, Inc [Member] | |||||||
| Total estimated clinical costs to be charged to operations | $ 2,233,248 | ||||||
| Percentage of clinical trial service | 60.00% | ||||||
| Percentage of clinical center laboratory cost | 40.00% | ||||||
| Clinical costs charged to operations | $ 0 | $ 64,615 | |||||
| Percentage of research and development costs | 0.00% | 41.00% | |||||
| X | ||||||||||
- Definition Clinical costs charged to operations. No definition available.
|
| X | ||||||||||
- Definition Current estimated cost of clinical trial. No definition available.
|
| X | ||||||||||
- Definition The amortization period for recovery of the deferred set-up and organization costs for Federal tax purposes. No definition available.
|
| X | ||||||||||
- Definition Patent and licensing costs. No definition available.
|
| X | ||||||||||
- Definition Percentage Of Clinical Center Laboratory Cost. No definition available.
|
| X | ||||||||||
- Definition Percentage of clinical research and development costs. No definition available.
|
| X | ||||||||||
- Definition Percentage Of Clinical Trial Service. No definition available.
|
| X | ||||||||||
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of unrecognized tax benefits. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|